NDC 85766-0212-03: Baqsimi glucagon 3 mg Powder, 1 tube
This is a package of 1 tube of Baqsimi glucagon 3 mg Powder from Sportpharm LLC, first listed with the FDA Jul 2019 and currently FDA-listed. It is this product's only package size.
NDC database record
One package, one record: these facts belong to NDC 85766-212-03 alone.
- Record
- FDA NDC Directory package listing · Human prescription drug
- Code segments
- 85766 labeler · 212 product · 03 package
- Package marketed since
- Jun 19, 2026
- Sample package
- No — commercial package
- Listing certified through
- Dec 31, 2027
- Barcode (UPC-A, from the NDC)
- 3 8576621203 5
- FDA record last changed
- Jul 24, 2026
Other active recalls for Glucagon (different manufacturers) — 1 · tap to view
Identity & classification
Regulatory identifiers FDA, NLM and CMS codes for this package
- RxCUI (RxNorm): 2180666
Where does this data come from?
- FDA openFDA NDC Directory · synced Nov 19, 2026
- FDA label on DailyMed · label index refreshed Nov 21, 2026
- RxNorm (NLM RxNav) · catalog refreshed Nov 19, 2026
- Medi-Span GPI (licensed)
- First Databank (licensed) · refreshed Nov 19, 2026
RxNorm drug class
This medicine belongs to the Antihypoglycemic Agent class.
Where does this data come from?
- RxClass (NLM) · catalog refreshed Nov 19, 2026
Clinical
Glucagon nasal powder is used for emergency treatment of very low blood sugar (severe hypoglycemia). Glucagon nasal powder is in a class of medications called glycogenolytic agents. It works by causing the liver to release stored sugar to the blood.
Read the full MedlinePlus article ↗- It's an emergency treatment for severe low blood sugar in people with diabetes, ages 1 and older. It's for when the person can't fix a low on their own and needs someone else's hel...
- Put the tip in one nostril and press the plunger all the way in until the green line is gone. You don't need to inhale. Then call for emergency help right away. Don't test the devi...
- If there's no response after 15 minutes, you can give another dose from a new device while waiting for emergency help. Once the person responds, give oral carbohydrates to help kee...
- What if the person doesn't wake up or improve?
Patient education
Drug interactions
Supplement & herbal interactions
Some supplements/herbs that may interact with Glucagon — tap one for details:
Glucagon may be associated with lower levels of 1 nutrient — worth a chat with your pharmacist, not a cause for alarm.
Where does this data come from?
- MedlinePlus (NLM) · refreshed Nov 19, 2026
- FDA label on DailyMed · label index refreshed Nov 21, 2026
Ask a licensed pharmacist directly — free, answered by our team.
Pricing
A drug doesn't have one price. Each row is a different public payment system, and none is what you'd pay at the counter — that depends on your insurance. The ⓘ on each row explains what it measures.
| Price system | Per g | Per package |
|---|---|---|
| Retail pharmacies payNADAC · weekly | Not in the retail survey — common for institutional, discontinued, or low-volume packs. | |
| Medicaid paysCMS SDUD · 12 mo | No recent Medicaid claims on file for this NDC — rare and low-volume NDCs are suppressed in the public data. | |
| Medicare drug plans payPart D · Q2 2026 | $295.43 | — |
Where does this data come from?
- CMS NADAC weekly file
- CMS ASP pricing files · refreshed Nov 20, 2026
- CMS Medicaid State Drug Utilization Data · refreshed Nov 19, 2026
- CMS Part D plan pricing files · refreshed Oct 24, 2026
- VA National Acquisition Center price file
Packaging — all sizes for this product
| Package NDC | Description | Marketing start | Marketing end | Status |
|---|---|---|---|---|
| 85766-0212-03 You're viewing this Main listing | 1 TUBE in 1 CARTON / 1 BOTTLE, UNIT-DOSE in 1 TUBE / 1 POWDER in 1 BOTTLE, UNIT-DOSE | 2026-06-19 | — | Active |
Therapeutic equivalents
| Product | Labeler | Pack | NADAC/unit | TE | Status | Price vs. this |
|---|---|---|---|---|---|---|
| Baqsimi 3 mg 00548-8351-01 | Amphastar | 1 tube | $292.956 | — | Availability likely | — |
| Baqsimi 3 mg 00548-8352-02 | Amphastar | 2 tubes | $293.100 | — | Availability likely | — |
| Baqsimi 3 mgthis 85766-0212-03 | Sportpharm | 1 tube | — | — | FDA listed | — |
Where does this data come from?
- FDA openFDA NDC Directory · synced Nov 19, 2026
- FDA Orange Book · refreshed Nov 6, 2026
- CMS NADAC weekly file
Availability & generic status
We did not find an FDA-approved generic match for this exact strength, form and route. Patent/protection dates below may affect future generic timing.
Why the date isn’t exact: Generic timing can change because patents may be challenged, settled, licensed, added, removed, or worked around with a narrower label — and FDA approval does not always mean a pharmacy can get the generic today.
Our estimate: 2036 to 2040 a wide window
How sure: Probable. More likely than not, but it can still move.
Why then: A patent that protects the brand runs out. After that, approved generics can be sold.
That is before the September 2039 date above, which is common: a court ruling or a deal with the brand’s maker often lets a generic in before the last patent runs out.
See the full forecast for generic Baqsimi →🛈 What do these terms mean?
- Patent
- Legal protection listed in the Orange Book that may delay generic approval or launch. Issued by the U.S. Patent & Trademark Office.
- Substance patent
- Covers the active drug molecule itself — the hardest to design around. A generic generally can’t launch until it expires.
- Formulation (product) patent
- Covers a specific formulation or dosage form. A generic can sometimes work around it with a different formulation.
- Method-of-use patent
- A patent covering one specific approved use of the drug — not necessarily the whole molecule. A generic can sometimes launch with a “skinny label” that carves out the protected use and keeps the others.
- Skinny label
- A generic label that omits a still-patented use when the FDA allows it — letting a generic reach the market for the unprotected uses.
- Exclusivity
- FDA-granted marketing protection, separate from patents — e.g. 5-yr new chemical entity, 7-yr orphan drug, or a +6-month pediatric extension.
- Paragraph IV
- A generic applicant’s formal challenge to a listed patent. It can potentially lead to earlier generic entry, but often involves litigation or a settlement.
- RLD / RS
- Reference Listed Drug — the brand product the FDA uses as the reference for generic applications. Reference Standard — the product the FDA expects generics to compare against in bioequivalence testing.
- TE / AB rating
- FDA therapeutic-equivalence rating. An AB rating generally means the FDA considers a generic therapeutically equivalent to — and substitutable for — the brand.
- LOE (loss of exclusivity)
- The latest patent or exclusivity currently listed — the loss-of-exclusivity / latest-listed-protection date shown on this page. Paragraph-IV challenges and settlements can move the real date earlier; FDA approval and a manufacturer’s decision to market can move it later.
Built from the FDA Orange Book. The bars above are scaled to each protection’s expiry; the red LOE marker is the last one to lapse.
| Patent | Type | Use code | Expires |
|---|---|---|---|
| US 10213487 ↗ | Method of use | U-2604 | Feb 16, 2036 |
| US 12370241 ↗ | Method of use | U-2604 | Feb 16, 2036 |
| US 10765602 ↗ | Drug product | — | Sep 23, 2039 |
| Code | What it grants | Expires |
|---|---|---|
| NPP | New Patient Population | Mar 17, 2028 |
Is there a generic version of this drug?
The FDA approved a generic — why can’t I get it at my pharmacy yet?
Why do different websites show different generic release dates?
What does “FDA listed” mean?
What does a patent or protection date mean here?
What does “current Orange Book estimate” mean?
Can a generic come out before the last patent expires?
Can a generic come out after the listed dates?
What is the difference between patents and exclusivity?
Why are there multiple patent dates?
Where does this data come from?
- FDA Orange Book · refreshed Nov 6, 2026
Inactive Ingredients / Excipients
Inactive ingredients, also called excipients, are components of the drug product other than the active ingredient. They may include fillers, dyes, coatings, preservatives, flavors, or other formulation ingredients.
🧪 Avoiding an ingredient? See Glucagon Nasal Powder inactive ingredients by manufacturer: every current product's list side by side, so you can ask your pharmacy for the version that does not list it.
💡 Tap an ingredient (hover on desktop) to see what it is and why it’s used.
-
UNII Q40Q9N063P
Acetic acid is a weak organic acid commonly used in medicines as a buffer and pH adjuster. It helps maintain the proper acidity level to ensure the drug remains stable and effective in its formulation.
-
24 mg
UNII JV039JZZ3A
Betadex is a modified sugar molecule derived from starch. It acts as a solubilizer and stabilizer in medicines, helping dissolve poorly soluble drugs and keep them stable during storage.
-
3 mg
UNII M5CF6282DD
A synthetic surfactant (detergent-like molecule) derived from dodecanol and phosphocholine. It helps dissolve and stabilize active ingredients in liquid or semi-solid formulations.
-
UNII 059QF0KO0R
Water is a liquid solvent that dissolves and mixes ingredients together in liquid medicines, syrups, and injections. It helps distribute the active drug evenly throughout the product.
4 inactive ingredients listed in the exact product block matched to this NDC.
Where does this data come from?
ingredient classCode="IACT" elements from the exact product block matched by this NDC. Label-section narrative from DailyMed / the openFDA label index is shown separately when available.- FDA label on DailyMed · label index refreshed Nov 21, 2026
- FDA openFDA NDC Directory · synced Nov 19, 2026
Inactive ingredient FAQ
Are inactive ingredients the same for every manufacturer?
Why might an inactive ingredient be missing?
Can inactive ingredients matter?
Manufacturer & labeler
More NDCs from Sportpharm LLC labeler code 85766
- Triamcinolone Acetonide 200 mg/5mL Injection, Suspension NDC 85766-206-05
- Mupirocin 20 mg/g Ointment NDC 85766-207-15
- Ceftriaxone Sodium 250 mg Injection, Powder, For Solution NDC 85766-208-01
- Ceftriaxone Sodium 500 mg Injection, Powder, For Solution NDC 85766-209-01
- Ceftriaxone Sodium 1 g Injection, Powder, For Solution NDC 85766-210-01
- Lidocaine Hydrochloride 10 mg/mL Injection, Solution NDC 85766-211-05
- Ondansetron 4 mg Tablet, Orally Disintegrating NDC 85766-213-10
- Dexamethasone Sodium Phosphate 10 mg/mL Injection, Solution NDC 85766-214-10
- Dexamethasone Sodium Phosphate 4 mg/mL Injection, Solution NDC 85766-215-25
- Dexamethasone Sodium Phosphate 4 mg/mL Injection, Solution NDC 85766-216-25
- Dexamethasone Sodium Phosphate 4 mg/mL Injection, Solution NDC 85766-217-25
- Ibuprofen 400 mg Tablet NDC 85766-218-01
Where does this data come from?
- FDA openFDA NDC Directory · synced Nov 19, 2026
- Drugs@FDA
Full prescribing information FDA SPL
🎯 Indications and Usage ▾
1 INDICATIONS AND USAGE BAQSIMI™ is indicated for the treatment of severe hypoglycemia in adults and pediatric patients aged 1 year and older with diabetes. BAQSIMI ® is an antihypoglycemic agent indicated for the treatment of severe hypoglycemia in adults and pediatric patients aged 1 year and older with diabetes. ( 1 )
⏱️ Dosage and Administration ▾
2 DOSAGE AND ADMINISTRATION BAQSIMI is for intranasal use only. ( 2.1 ) The recommended dose of BAQSIMI is 3 mg administered as one actuation of the intranasal device into one nostril. ( 2.2 ) Administer BAQSIMI according to the printed instructions on the shrink-wrapped tube label and the Instructions for Use.
( 2.1 ) Administer the dose by inserting the tip into one nostril and pressing the device plunger all the way in until the green line is no longer showing. The dose does not need to be inhaled. ( 2.1 ) Call for emergency assistance immediately after administering the dose.
( 2.1 ) When the patient responds to treatment, give oral carbohydrates. ( 2.1 ) Do not attempt to reuse BAQSIMI. Each BAQSIMI device contains one dose of glucagon and cannot be reused.
Discard any unused portion. ( 2.1 ) If there has been no response after 15 minutes, an additional 3 mg dose may be administered while waiting for emergency assistance. ( 2.2 )
2.1Important Administration Instructions BAQSIMI is for intranasal use only. Instruct patients and their caregivers on the signs and symptoms of severe hypoglycemia. Because severe hypoglycemia requires help of others to recover, instruct the patient to inform those around them about BAQSIMI and its Instructions for Use.
Administer BAQSIMI as soon as possible when severe hypoglycemia is recognized. Instruct the patient or caregiver to read the Instructions for Use at the time they receive a prescription for BAQSIMI. Emphasize the following instructions to the patient or caregiver: Do not push the plunger or test the device prior to administration.
Administer BAQSIMI according to the printed instructions on the shrink-wrapped tube label and the Instructions for Use. Administer the dose by inserting the tip into one nostril and pressing the device plunger all the way in until the green line is no longer showing. The dose does not need to be inhaled.
Call for emergency assistance immediately after administering the dose. If there has been no response after 15 minutes, an additional dose of BAQSIMI may be administered while waiting for emergency assistance. When the patient responds to treatment, give oral carbohydrates to restore the liver glycogen and prevent recurrence of hypoglycemia.
Do not attempt to reuse BAQSIMI. Each BAQSIMI device contains one dose of glucagon and cannot be reused. Discard any unused portion.
2.2Dosage in Adults and Pediatric Patients Aged 1 Year and Older The recommended dose of BAQSIMI is 3 mg administered as one actuation of the intranasal device into one nostril. If there has been no response after 15 minutes, an additional 3 mg dose of BAQSIMI from a new device may be administered while waiting for emergency assistance.
💊 Dosage Forms and Strengths ▾
3 DOSAGE FORMS AND STRENGTHS Nasal Powder: 3 mg glucagon: as a white powder in an intranasal device containing one dose of glucagon Nasal powder: intranasal device containing one dose of glucagon 3 mg ( 3 )
⛔ Contraindications ▾
4 CONTRAINDICATIONS BAQSIMI is contraindicated in patients with: Pheochromocytoma because of the risk of substantial increase in blood pressure [see Warnings and Precautions ( 5.1 )] Insulinoma because of the risk of hypoglycemia [see Warnings and Precautions ( 5.2 )] Prior hypersensitivity reaction to glucagon or to any of the excipients in BAQSIMI. Allergic reactions have been reported with glucagon and include anaphylactic shock with breathing difficulties and hypotension [see Warnings and Precautions ( 5.3 )] Pheochromocytoma ( 4 ) Insulinoma ( 4 ) Known hypersensitivity to glucagon or to any of the excipients ( 4 )
⚠️ Warnings and Cautions ▾
5 WARNINGS AND PRECAUTIONS Substantial Increase in Blood Pressure in Patients with Pheochromocytoma : Contraindicated in patients with pheochromocytoma because BAQSIMI may stimulate the release of catecholamines from the tumor. ( 5.1 ) Hypoglycemia in Patients with Insulinoma : In patients with insulinoma, administration may produce an initial increase in blood glucose; however, BAQSIMI may stimulate exaggerated insulin release from an insulinoma and cause hypoglycemia. If a patient develops symptoms of hypoglycemia after a dose of BAQSIMI, give glucose orally or intravenously.
( 5.2 ) Serious Hypersensitivity Reactions : Serious hypersensitivity reactions have been reported and include generalized rash, and in some cases anaphylactic shock with breathing difficulties, and hypotension. ( 5.3 ) Lack of Efficacy in Patients with Decreased Hepatic Glycogen : BAQSIMI is effective in treating hypoglycemia only if sufficient hepatic glycogen is present. Patients in states of starvation, with adrenal insufficiency or chronic hypoglycemia may not have adequate levels of hepatic glycogen for BAQSIMI to be effective.
Patients with these conditions should be treated with glucose. ( 5.4 )
5.1Substantial Increase in Blood Pressure in Patients with Pheochromocytoma BAQSIMI is contraindicated in patients with pheochromocytoma because glucagon may stimulate release of catecholamines from the tumor [see Contraindications ( 4 )]. If the patient develops a substantial increase in blood pressure and a previously undiagnosed pheochromocytoma is suspected, 5 to 10 mg of phentolamine mesylate, administered intravenously, has been shown to be effective in lowering blood pressure.
5.2Hypoglycemia in Patients with Insulinoma In patients with insulinoma, administration of glucagon may produce an initial increase in blood glucose; however, BAQSIMI administration may directly or indirectly (through an initial rise in blood glucose) stimulate exaggerated insulin release from an insulinoma and cause hypoglycemia. BAQSIMI is contraindicated in patients with insulinoma [see Contraindications ( 4 )]. If a patient develops symptoms of hypoglycemia after a dose of BAQSIMI, give glucose orally or intravenously.
5.3Serious Hypersensitivity Reactions Serious hypersensitivity reactions have been reported with glucagon products, including generalized rash, and in some cases anaphylactic shock with breathing difficulties and hypotension. Discontinue BAQSIMI if symptoms of serious hypersensitivity reactions occur. Advise patients and/or caregivers to seek immediate medical attention if the patient experiences any symptoms of serious hypersensitivity reactions.
BAQSIMI is contraindicated in patients with a prior hypersensitivity reaction [see Contraindications ( 4 )].
5.4Lack of Efficacy in Patients with Decreased Hepatic Glycogen Patients with insufficient hepatic stores of glycogen may not respond to BAQSIMI for the treatment of severe hypoglycemia [see Clinical Pharmacology ( 12.2 )]. Insufficient hepatic stores of glycogen may be present in conditions such as states of starvation or in patients with adrenal insufficiency or chronic hypoglycemia.
🤒 Adverse Reactions ▾
6 ADVERSE REACTIONS The following clinically significant adverse reactions are described elsewhere in labeling: Substantial Increase in Blood Pressure in Patients with Pheochromocytoma [see Warnings and Precautions ( 5.1 )] . Hypoglycemia in Patients with Insulinoma [see Warnings and Precautions ( 5.2 )] . Serious Hypersensitivity Reactions [see Warnings and Precautions ( 5.3 )] .
Lack of Efficacy in Patients with Decreased Hepatic Glycogen [see Warnings and Precautions ( 5.4 )] . Most common (≥10%) adverse reactions associated with BAQSIMI are nausea, vomiting, headache, upper respiratory tract irritation (i.e., rhinorrhea, nasal discomfort, nasal congestion, cough, and epistaxis), watery eyes, redness of eyes, itchy nose, throat and eyes. ( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Amphastar Pharmaceuticals, Inc. at 1-800-423-4136 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
6.1Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of BAQSIMI cannot be directly compared with rates in clinical trials of other drugs and may not reflect the rates observed in practice. Adverse Reactions in Adult Patients Two similarly designed comparator-controlled trials, Study 1 and Study 2, evaluated the safety of a single intranasal dose of BAQSIMI compared to a 1 mg dose of intra-muscular glucagon (IMG) in adult patients with diabetes [see Clinical Studies ( 14.1 )].
Table 1 presents adverse reactions that occurred with BAQSIMI at an incidence of ≥2% in a pool of Study 1 and Study 2. Table 1: Pooled Adverse Reactions (≥2%) in Adult Patients with Type 1 and Type 2 Diabetes in Study 1and Study 2 a Upper Respiratory Tract Irritation: rhinorrhea, nasal discomfort, nasal congestion, cough, and epistaxis. Adverse Reaction BAQSIMI 3 mg (N=153) % Nausea 26 Headache 18 Vomiting 15 Upper Respiratory Tract Irritation a 12 Nasal and ocular symptoms with BAQSIMI were solicited through a patient questionnaire in Study 1 and 2 and these adverse reactions are presented in Table 2 .
Table 2: Solicited Nasal and Non-Nasal Adverse Reactions in Adult Patients with Type 1 and Type 2 Diabetes Pooled from Study 1 and 2 a Patients were asked to report whether they have the symptom, as well as severity (mild, moderate, severe) at baseline, and after glucagon administration. Adverse Reaction a BAQSIMI 3 mg (n=153) % Any increase in symptom severity a Watery eyes 59 Nasal congestion 43 Nasal itching 39 Runny nose 35 Redness of eyes 25 Itchy eyes 22 Sneezing 20 Itching of throat 12 Itching of ears 3 Adverse Reactions in Pediatric Patients Aged 1 Year and Above A single dose of BAQSIMI was compared to weight-based doses of 0.5 mg or 1 mg of IMG in pediatric patients aged 4 to less than 17 years with type 1 diabetes in Study 3 [see Clinical Studies ( 14.2 )].
Table 3 presents adverse reactions that occurred with BAQSIMI in pediatric patients at an incidence of ≥2% in Study 3. Table 3: Adverse Reactions (≥2%) Occurring in Pediatric Patients Aged 4 to less than 17 Years with Type 1 Diabetes in Study 3 a Upper Respiratory Tract Irritation: nasal discomfort, nasal congestion, sneezing. Adverse Reaction BAQSIMI 3 mg (n=36) % Vomiting 31 Headache 25 Nausea 17 Upper Respiratory Tract Irritation a 17 Nasal and ocular symptoms with BAQSIMI were solicited through a patient questionnaire in pediatric patients in Study 3 and these adverse reactions are presented in Table 4 .
Table 4: Solicited Nasal and Non-Nasal Adverse Reactions in Pediatric Patients Aged 4 to less than 17 Years with Type 1 Diabetes in Study 3 a Subjects were asked to report whether they have the symptom, as well as severity (mild, moderate, severe) at baseline, and after glucagon administration. Adverse Reaction a BAQSIMI 3 mg (n=36) % Any increase in symptom severity a Watery eyes 47 Nasal congestion 42 Nasal itching 28 Runny nose 25 Sneezing 19 Itchy eyes 17 Redness of eyes 14 Itching of throat 3… [Excerpted — this section continues on DailyMed.]
🔄 Drug Interactions ▾
7 DRUG INTERACTIONS Beta-blockers : Patients taking beta-blockers may have a transient increase in pulse and blood pressure. ( 7.1 ) Indomethacin : In patients taking indomethacin BAQSIMI may lose its ability to raise glucose or may produce hypoglycemia. ( 7.2 ) Warfarin : BAQSIMI may increase the anticoagulant effect of warfarin. ( 7.3 )
7.1Beta-blockers Patients taking beta-blockers may have a transient increase in pulse and blood pressure when given BAQSIMI.
7.2Indomethacin In patients taking indomethacin, BAQSIMI may lose its ability to raise blood glucose or may even produce hypoglycemia.
7.3Warfarin BAQSIMI may increase the anticoagulant effect of warfarin.
👥 Use in Specific Populations ▾
8 USE IN SPECIFIC POPULATIONS
8.1Pregnancy Risk Summary Available data from case reports and a small number of observational studies with glucagon use in pregnant women over decades of use have not identified a drug associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes. Multiple small studies have demonstrated a lack of transfer of pancreatic glucagon across the human placental barrier during early gestation. In a rat reproduction study, no embryofetal toxicity was observed with glucagon administered by injection during the period of organogenesis at doses representing up to 40 times the human dose, based on body surface area (mg/m 2 ) (see Data).
The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively. Data Animal Data In pregnant rats given animal sourced glucagon twice-daily by injection at doses up to 2 mg/kg (up to 40 times the human dose based on body surface area extrapolation, mg/m 2 ) during the period of organogenesis, there was no evidence of increased malformations or embryofetal lethality.
8.2Lactation Risk Summary There is no information available on the presence of glucagon in human or animal milk, the effects of the drug on the breastfed infant, or the effects of the drug on milk production. However, glucagon is a peptide and would be expected to be broken down to its constituent amino acids in the infant's digestive tract and is therefore, unlikely to cause harm to an exposed infant.
8.4Pediatric Use The safety and effectiveness of BAQSIMI for the treatment of severe hypoglycemia in patients with diabetes have been established in pediatric patients aged 1 year and older. Use of BAQSIMI for this indication is supported by evidence from an adequate and well-controlled study in adults with type 1 diabetes mellitus [see Clinical Studies ( 14.1 )] , a study in 48 pediatric patients aged 4 to less than 17 years with type 1 diabetes mellitus [see Clinical Studies ( 14.2 )] , and additional pharmacokinetic and safety data from a study of seven pediatric patients aged 1 to less than 4 years with type 1 diabetes mellitus [see Adverse Reactions ( 6.1 ),Clinical Pharmacology ( 12.2 , 12.3 ), and Clinical Studies ( 14.2 )] .
The safety and effectiveness of BAQSIMI have not been established in pediatric patients younger than 1 year of age.
8.5Geriatric Use Clinical studies of BAQSIMI did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger adult patients.
🤰 Pregnancy ▾
8.1Pregnancy Risk Summary Available data from case reports and a small number of observational studies with glucagon use in pregnant women over decades of use have not identified a drug associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes. Multiple small studies have demonstrated a lack of transfer of pancreatic glucagon across the human placental barrier during early gestation. In a rat reproduction study, no embryofetal toxicity was observed with glucagon administered by injection during the period of organogenesis at doses representing up to 40 times the human dose, based on body surface area (mg/m 2 ) (see Data).
The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively. Data Animal Data In pregnant rats given animal sourced glucagon twice-daily by injection at doses up to 2 mg/kg (up to 40 times the human dose based on body surface area extrapolation, mg/m 2 ) during the period of organogenesis, there was no evidence of increased malformations or embryofetal lethality.
🧒 Pediatric Use ▾
8.4Pediatric Use The safety and effectiveness of BAQSIMI for the treatment of severe hypoglycemia in patients with diabetes have been established in pediatric patients aged 1 year and older. Use of BAQSIMI for this indication is supported by evidence from an adequate and well-controlled study in adults with type 1 diabetes mellitus [see Clinical Studies ( 14.1 )] , a study in 48 pediatric patients aged 4 to less than 17 years with type 1 diabetes mellitus [see Clinical Studies ( 14.2 )] , and additional pharmacokinetic and safety data from a study of seven pediatric patients aged 1 to less than 4 years with type 1 diabetes mellitus [see Adverse Reactions ( 6.1 ),Clinical Pharmacology ( 12.2 , 12.3 ), and Clinical Studies ( 14.2 )] .
The safety and effectiveness of BAQSIMI have not been established in pediatric patients younger than 1 year of age.
🧓 Geriatric Use ▾
8.5Geriatric Use Clinical studies of BAQSIMI did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger adult patients.
🆘 Overdosage ▾
10 OVERDOSAGE If overdosage occurs, the patient may experience nausea, vomiting, inhibition of GI tract motility, increase in blood pressure and pulse rate. In case of suspected overdosing, serum potassium levels may decrease and should be monitored and corrected if needed. If the patient develops a dramatic increase in blood pressure, phentolamine mesylate has been shown to be effective in lowering blood pressure for the short time that control would be needed.
In the event of an overdose of BAQSIMI, consider contacting the Poison Help line (1-800-222-1222) or a medical toxicologist for additional overdosage management recommendation.
🧬 Clinical Pharmacology ▾
12 CLINICAL PHARMACOLOGY
12.1Mechanism of Action Glucagon increases blood glucose concentration by activating hepatic glucagon receptors, thereby stimulating glycogen breakdown and release of glucose from the liver. Hepatic stores of glycogen are necessary for glucagon to produce an antihypoglycemic effect.
12.2Pharmacodynamics After administration of BAQSIMI in adult patients with diabetes, the mean maximum glucose increase from baseline was 140 mg/dL ( Figure 1 ). In pediatric patients aged 1 to less than 17 years with type 1 diabetes, the mean maximum glucose increase from baseline was 132 mg/dL (1 to less than 4 years), 138 mg/dL (4 to less than 8 years), 133 mg/dL (8 to less than 12 years), and 102 mg/dL (12 to less than 17 years) ( Figure 2 ). Sex and body weight had no clinically meaningful effects on the pharmacodynamics of BAQSIMI.
Common cold with nasal congestion tested with or without use of decongestant did not impact pharmacodynamics of BAQSIMI. Figure 1 Mean glucose concentration over time after glucagon dose in adult Type 1 Diabetes patients with insulin-induced hypoglycemia. Fi gure 2 Mean glucose concentration over time in pediatric Type 1 Diabetes patients administered BAQSIMI figure1 figure2
12.3Pharmacokinetics Absorption Glucagon absorption via the intranasal route, achieved mean peak plasma levels of 6130 pg/mL at around 15 minutes. Distribution The apparent volume of distribution was approximately 885 L. Elimination The median half-life was approximately 35 minutes.
Metabolism Glucagon is known to be degraded in the liver, kidneys, and plasma. Specific Populations Pediatrics In pediatric patients (aged 1 to less than 17 years), glucagon via the intranasal route, achieved mean peak plasma levels between 10 and 20 minutes. The median half-life was 21 to 31 minutes.
Patients with Colds Common cold with nasal congestion did not impact the pharmacokinetics of BAQSIMI. Drug Interaction Studies Common cold with use of decongestant did not impact the pharmacokinetics of BAQSIMI.
12.6Immunogenicity The observed incidence of anti-drug antibodies (ADA) is highly dependent on the sensitivity and specificity of the assay. Differences in assay methods preclude meaningful comparisons of the incidence of ADA in the studies described below with the incidence of anti-drug antibodies in other studies, including those of glucagon or of other glucagon products. In 3 clinical trials, 3/124 (2%) of BAQSIMI-treated patients had treatment-emergent ADAs as detected by an affinity capture elution (ACE) ligand-binding immunogenicity assay.
No neutralizing antibodies were detected. Because of the low occurrence of ADA, the effect of these antibodies on the pharmacokinetics, pharmacodynamics, and/or effectiveness of BAQSIMI is unknown.
🧬 Mechanism of Action ▾
12.1Mechanism of Action Glucagon increases blood glucose concentration by activating hepatic glucagon receptors, thereby stimulating glycogen breakdown and release of glucose from the liver. Hepatic stores of glycogen are necessary for glucagon to produce an antihypoglycemic effect.
📦 How Supplied / Storage and Handling ▾
16 HOW SUPPLIED/STORAGE AND HANDLING BAQSIMI is supplied as an intranasal device containing one 3 mg dose of glucagon as a preservative free, white powder. BAQSIMI One Pack carton contains 1 intranasal device (NDC 85766-212-03 relabeled from NDC 0548-8351-01) Store at temperatures up to 86°F (30°C) in the shrink wrapped tube provided. Keep BAQSIMI in the shrink wrapped tube until ready to use.
If the tube has been opened, BAQSIMI may have been exposed to moisture and may not work as expected. Discard BAQSIMI and tube after use.
📋 Description ▾
11 DESCRIPTION BAQSIMI contains glucagon, an antihypoglycemic agent used to treat severe hypoglycemia. Glucagon is a single-chain polypeptide containing 29 amino acid residues and has a molecular weight of 3483, and is identical to human glucagon. Its molecular formula is C 153 H 225 N 43 O 49 S, with the following molecular structure: BAQSIMI is a preservative-free, white powder for intranasal administration in an intranasal device containing one dose of 3 mg glucagon.
BAQSIMI contains glucagon as the active ingredient and betadex, and dodecylphosphocholine as the excipients. structure
💬 Information for Patients ▾
17 PATIENT COUNSELING INFORMATION Advise the patient and family members or caregivers to read the FDA-approved patient labeling ( Patient Information and Instructions for Use ). Recognition of Severe Hypoglycemia: Inform patient and family members or caregivers on how to recognize the signs and symptoms of severe hypoglycemia and the risks of prolonged hypoglycemia. Serious Hypersensitivity Reactions: Inform patients that serious hypersensitivity reactions can occur with BAQSIMI.
Advise patients to seek immediate medical attention if they experience any symptoms of serious hypersensitivity reactions [see Warnings and Precautions ( 5.3 )] . Distributed by: Sportpharm LLC 379 Van Ness Ave 1401, Torrance, CA 90501 Relabeled by: Enovachem PHARMACEUTICALS Torrance, CA 90501
🧬 Pharmacokinetics ▾
12.3Pharmacokinetics Absorption Glucagon absorption via the intranasal route, achieved mean peak plasma levels of 6130 pg/mL at around 15 minutes. Distribution The apparent volume of distribution was approximately 885 L. Elimination The median half-life was approximately 35 minutes.
Metabolism Glucagon is known to be degraded in the liver, kidneys, and plasma. Specific Populations Pediatrics In pediatric patients (aged 1 to less than 17 years), glucagon via the intranasal route, achieved mean peak plasma levels between 10 and 20 minutes. The median half-life was 21 to 31 minutes.
Patients with Colds Common cold with nasal congestion did not impact the pharmacokinetics of BAQSIMI. Drug Interaction Studies Common cold with use of decongestant did not impact the pharmacokinetics of BAQSIMI.
🧬 Pharmacodynamics ▾
12.2Pharmacodynamics After administration of BAQSIMI in adult patients with diabetes, the mean maximum glucose increase from baseline was 140 mg/dL ( Figure 1 ). In pediatric patients aged 1 to less than 17 years with type 1 diabetes, the mean maximum glucose increase from baseline was 132 mg/dL (1 to less than 4 years), 138 mg/dL (4 to less than 8 years), 133 mg/dL (8 to less than 12 years), and 102 mg/dL (12 to less than 17 years) ( Figure 2 ). Sex and body weight had no clinically meaningful effects on the pharmacodynamics of BAQSIMI.
Common cold with nasal congestion tested with or without use of decongestant did not impact pharmacodynamics of BAQSIMI. Figure 1 Mean glucose concentration over time after glucagon dose in adult Type 1 Diabetes patients with insulin-induced hypoglycemia. Fi gure 2 Mean glucose concentration over time in pediatric Type 1 Diabetes patients administered BAQSIMI figure1 figure2
🔬 Clinical Studies ▾
14 CLINICAL STUDIES
14.1Adult Patients with Type 1 or Type 2 Diabetes Mellitus Study 1 ( NCT03339453 ) was a randomized, multicenter, open-label, 2-period, crossover study in adult patients with type 1 diabetes. The efficacy of a single 3 mg dose of BAQSIMI was compared to a 1 mg dose of intra-muscular glucagon (IMG). Insulin was used to reduce blood glucose levels to <60 mg/dL.
Seventy patients were enrolled, with a mean age of 41.7 years and a mean diabetes duration of 20.1 years. Twenty-seven (39%) were female. The primary efficacy outcome measure was the proportion of patients achieving treatment success, which was defined as either an increase in blood glucose to ≥70 mg/dL or an increase of ≥20 mg/dL from glucose nadir within 30 minutes after receiving study glucagon, without receiving additional actions to increase the blood glucose level.
Glucose nadir was defined as the minimum glucose measurement at the time of, or within 10 minutes, following glucagon administration. The mean nadir blood glucose was 54.5 mg/dL for BAQSIMI and 55.8 mg/dL for IMG. BAQSIMI demonstrated non-inferiority to IMG in reversing insulin-induced hypoglycemia with 100% of BAQSIMI-treated patients and 100% of IMG-treated patients achieving treatment success.
The mean time to treatment success was 11.6 and 9.9 minutes in the BAQSIMI and IMG 1 mg treatment groups, respectively. Table 5: Adult Patients with Type 1 Diabetes Meeting Treatment Success and Other Glucose Criteria in Study 1 a The Efficacy Analysis Population consisted of all patients who received both doses of the Study Drug with evaluable primary outcome. b Difference calculated as (percentage with success in BAQSIMI) – (percentage with success in IMG). c 2-sided 95% confidence interval (CI) of paired differences using a Wald-Min correction; non-inferiority margin = -10%.
Type 1 Diabetes (N=66) a BAQSIMI 3 mg IMG 1 mg Treatment Success – n (%) 66 (100%) 66 (100%) Treatment Difference (2-sided 95% confidence limit) b, c 0% (-2.9%, 2.9%) Glucose criterion met – n (%) (i) ≥70 mg/dL (ii) Increase by ≥20 mg/dL from nadir Both (i) and (ii) 66 (100%) 66 (100%) 66 (100%) 66 (100%) 66 (100%) 66 (100%) Study 2 ( NCT01994746 ) was a randomized, multicenter, open-label, 2-period, crossover study in adult patients with type 1 diabetes or type 2 diabetes. The efficacy of a single 3 mg dose of BAQSIMI was compared to a 1 mg dose of intra-muscular glucagon (IMG).
Insulin was used to reduce blood glucose levels to the hypoglycemic range with a target blood glucose nadir of <50 mg/dL. Study 2 enrolled 83 patients 18 to <65 years of age. The mean age of patients with type 1 diabetes (N=77) was 32.9 years and a mean diabetes duration of 18.1 years, and 45 (58%) patients were female.
The mean age of patients with type 2 diabetes (N=6) was 47.8 years, with a mean diabetes duration of 18.8 years, and 4 (67%) patients were female. The mean nadir blood glucose was 44.2 mg/dL for BAQSIMI and 47.2 mg/dL for IMG. BAQSIMI demonstrated non-inferiority to IMG in reversing insulin-induced hypoglycemia with 98.8% of BAQSIMI-treated patients and 100% of IMG-treated patients achieving treatment success within 30 minutes.
The mean time to treatment success was 15.9 and 12.1 minutes in the BAQSIMI and IMG 1 mg treatment groups, respectively. Table 6: Adult Patients with Type 1 and Type 2 Diabetes Meeting Treatment Success and Other Glucose Criteria in Study 2 a The Efficacy Analysis Population consisted of all patients who received both doses of the Study Drug with evaluable primary outcome. b Difference calculated as (percentage with success in BAQSIMI) – (percentage with success in IMG). c 2-sided 95% confidence interval (CI) of paired differences using a Wald-Min correction; non-inferiority margin = -10%. d Percentage based on number of patients.
Type 1 and Type 2 Diabetes (N=80) a BAQSIMI 3 mg IMG 1 mg Treatment Success – n (%) 79 (98.8%) 80 (100%) Treatment Difference (2-sided 95% confidence limit) b,c -1.3% (-4.6%, 2… [Excerpted — this section continues on DailyMed.]
🧪 Nonclinical Toxicology ▾
13 NONCLINICAL TOXICOLOGY
13.1Carcinogenesis, Mutagenesis, Impairment of Fertility Long term studies in animals to evaluate carcinogenic potential have not been performed. Recombinant glucagon was positive in the bacterial Ames assay. It was determined that an increase in colony counts was related to technical difficulties in running this assay with peptides. Studies in rats have shown that glucagon does not cause impaired fertility.
📄 Carcinogenesis, Mutagenesis, Impairment of Fertility ▾
13.1Carcinogenesis, Mutagenesis, Impairment of Fertility Long term studies in animals to evaluate carcinogenic potential have not been performed. Recombinant glucagon was positive in the bacterial Ames assay. It was determined that an increase in colony counts was related to technical difficulties in running this assay with peptides. Studies in rats have shown that glucagon does not cause impaired fertility.
📄 Patient Package Insert ▾
This Patient Information has been approved by the U.S. Food and Drug Administration Issued: April, 2025 PATIENT INFORMATION BAQSIMI ® (BAK-see-mee) (glucagon) nasal powder What is BAQSIMI? BAQSIMI is a prescription medicine used to treat very low blood sugar (severe hypoglycemia) in people with diabetes ages 1 year and above.
It is not known if BAQSIMI is safe and effective in children under 1 year of age. Do not use BAQSIMI if you: have a tumor in the gland on top of your kidneys (adrenal gland) called pheochromocytoma. have a tumor in your pancreas called insulinoma. have had an allergic reaction to glucagon, or any of the ingredients in BAQSIMI. See the end of this Patient Information leaflet for a complete list of ingredients in BAQSIMI.
Talk with your healthcare provider before taking this medicine if you have any of these conditions. Before using BAQSIMI, tell your healthcare provider about all of your medical conditions, including if you: have adrenal gland problems. have a tumor in your pancreas. have not had food or water for a long time (prolonged fasting or starvation). have low blood sugar that does not go away (chronic hypoglycemia). are pregnant or plan to become pregnant. It is not known if BAQSIMI will harm your unborn baby. are breastfeeding or plan to breastfeed.
It is not known if BAQSIMI passes into your breast milk. You and your healthcare provider should decide if you can use BAQSIMI while breastfeeding. Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.
How should I use BAQSIMI? Read the detailed Instructions for Use that comes with BAQSIMI. Use BAQSIMI exactly how your healthcare provider tells you to use it.
Make sure your caregiver and those around you know where you keep your BAQSIMI and how to use BAQSIMI the right way before you need their help. BAQSIMI contains only 1 dose of medicine and cannot be reused. BAQSIMI should be given in one side of your nose (nostril) but does not need to be inhaled.
BAQSIMI will work even if you have a cold or are taking cold medicine. Act quickly. Having very low blood sugar for a period of time may be harmful.
After giving BAQSIMI, the caregiver should call for emergency medical help right away . When you are able to safely swallow food or drink, your caregiver should give you a fast-acting source of sugar (such as a regular soft drink or fruit juice) and a long-acting source of sugar (such as crackers with cheese or peanut butter). If the person does not respond after 15 minutes, another dose of BAQSIMI from a new device may be given, if available while waiting for emergency services.
Tell your healthcare provider each time you use BAQSIMI. What are the possible side effects of BAQSIMI? BAQSIMI may cause serious side effects, including: High blood pressure.
BAQSIMI can cause high blood pressure in certain people with tumors in their adrenal glands. Low blood sugar. BAQSIMI can cause certain people with tumors in their pancreas called insulinomas to have low blood sugar.
Serious allergic reaction. Call your healthcare provider or get medical help right away if you have a serious allergic reaction including: rash hives cough difficulty breathing trouble swallowing swelling of face, lips, or tongue low blood pressure feeling dizzy or faint fast heartbeat The most common side effects of BAQSIMI include: nausea vomiting headache runny nose discomfort in your nose stuffy nose cough nose bleed watery eyes redness in your eyes itchy nose, throat, and eyes These are not all the possible side effects of BAQSIMI.
For more information, ask your healthcare provider. Call your healthcare provider for medical advice about side effects. You may report side effects to the FDA at 1-800-FDA-1088.
How should I store BAQSIMI? Store BAQSIMI at temperatures up to 86ºF (30ºC). Keep BAQSIMI in the shrink wrapped tube until you are ready to use it.
Throw away (discard) BAQSIMI and tube aft… [Excerpted — this section continues on DailyMed.]
📖 Instructions for Use ▾
INSTRUCTIONS FOR USE BAQSIMI ® (glucagon) nasal powder 3 mg Read the Instructions for Use for BAQSIMI before using it. BAQSIMI is used to treat very low blood sugar (severe hypoglycemia) that will cause you to need help from others. You should make sure you show your caregivers, family and friends where you keep BAQSIMI and explain how to use it by sharing these instructions.
They need to know how to use BAQSIMI before an emergency happens. Tube and Device Parts Important Information to Know Do not remove the Shrink Wrap or open the Tube until you are ready to use it. If the Tube has been opened, BAQSIMI could be exposed to moisture.
This could cause BAQSIMI not to not work as expected. Do not push the plunger or test BAQSIMI before you are ready to use it. BAQSIMI contains 1 dose of glucagon nasal powder and cannot be reused.
BAQSIMI is for nasal (nose) use only. BAQSIMI will work even if you have a cold or are taking cold medicine. Preparing the Dose Remove the Shrink Wrap by pulling on red stripe.
Open the Lid and remove the Device from the Tube. Caution: Do not press the Plunger until ready to give the dose. Giving the Dose Hold Device between fingers and thumb.
Do not push Plunger yet. Insert Tip gently into one nostril until finger(s) touch the outside of the nose. Push Plunger firmly all the way in.
Dose is complete when the Green Line disappears. After giving BAQSIMI Call for emergency medical help right away. If the person is passed out (unconscious) turn the person on their side.
Encourage the person to eat as soon as possible. When they can safely swallow, give the person a fast-acting source of sugar such as juice. Then encourage the person to eat a snack such as crackers with cheese or peanut butter.
If the person does not respond after 15 minutes, another dose may be given, if available. Storage and Handling Do not remove the Shrink Wrap or open the Tube until you are ready to use it. Store BAQSIMI in the shrink wrapped Tube at temperatures up to 86º F (30ºC ).
Throw away (discard) BAQSIMI and Tube after use. Used BAQSIMI may be placed in household trash. Caution: Replace the used BAQSIMI right away so you will have a new BAQSIMI in case you need it.
Replace BAQSIMI before the expiration date printed on the Tube or carton. Keep BAQSIMI and all medicines out of the reach of children. For Questions or More Information about BAQSIMI Call your healthcare provider Call Amphastar Pharmaceuticals, Inc. at 1-800-423-4136 Visit www.baqsimi.com BAQSIMI is a registered trademark of Amphastar Pharmaceuticals, Inc.
Distributed by: Sportpharm LLC 379 Van Ness Ave 1401, Torrance, CA 90501 Relabeled by: Enovachem PHARMACEUTICALS Torrance, CA 90501 Copyright © 2025, Amphastar Pharmaceuticals, Inc. BAQSIMI Device meets all applicable requirements defined in ISO 20072 This Instructions for Use has been approved by the U.S. Food and Drug Adminstration Revised: March, 2025 678351AMC/3-25 ifu1 ifu2 ifu3 ifu4 ifu5 ifu6 ifu7
📄 Recent Major Changes ▾
Indications and Usage ( 1 )……………………………………….03/2025
📄 Package Label / Principal Display Panel ▾
PRINCIPAL DISPLAY PANEL label
Medicare Part D spend CMS · PART D · 2026 (Q1)
Reported adverse events (FAERS)
Top reported reactions
Age at onset
Reporter sex
Serious outcomes
Where does this data come from?
About this NDC listing & data coverage
What data is (and isn’t) available for this NDC — tap to expand
| NDC identity (package / product / labeler codes) | ✓ Available |
| Labeler | ✓ Available |
| Product & package description | ✓ Available |
| Marketing category & status | ✓ Available |
| Active ingredient / dosage form / route | ✓ Available |
| FDA label (SPL via DailyMed) | ✓ Available |
| Package photos | ✓ Available |
| Inactive ingredients (structured) | ✓ Available |
| NADAC pharmacy acquisition price (CMS) | — Not published for this NDC CMS publishes NADAC only for NDCs reported in its retail-pharmacy survey. |
| Orange Book / therapeutic-equivalence data | ✓ Available |
| HCPCS J-code billing crosswalk | — Not published for this NDC Most self-administered / retail products have no J-code — that is normal. |
| Medicaid utilization (CMS SDUD) | — Not published for this NDC CMS reports utilization only for NDCs with Medicaid claims above its privacy threshold. |